Avenzo Therapeutics Added Two Executive Leaders
The San Diego biotech hired two veterans to lead its investor relations and business development departments.
Updated on Sept. 28, 2026 in People
Live Poll
Do you trust that new leadership at emerging biotech firms signals long-term stability for investors?
Avenzo Therapeutics appointed Annie Chang and Aaron Hasnain as senior vice presidents to expand its leadership team. The move comes as the San Diego-based firm prepares for a transition to a public company.
Why it matters
The appointments strengthen internal capabilities for managing public-market expectations and forming strategic partnerships. Expanding the executive suite is a common precursor to the operational shifts required for a public listing.
The new leadership team brings a combined 35 years of professional experience to the firm. This expansion supports the company as it advances its oncology pipeline and scales its corporate structure.
The players
Avenzo Therapeutics
A San Diego-based biotechnology firm focused on developing oncology therapies.
Annie Chang
A corporate communications and investor relations expert with 20 years of experience in finance and biotech.
Aaron Hasnain
A business development leader with 15 years of experience in strategic partnerships and alliance management.
The details
Avenzo Therapeutics selected both executives for their track records at other biotechnology companies to bolster its transition phase. Annie Chang, formerly of 89bio, will oversee investor relations and corporate communications. Aaron Hasnain, previously at Gossamer Bio, will lead the business development and alliance management units to drive future strategic partnerships.
Timeline
September 28, 2026: Avenzo Therapeutics announced the appointment of two executives.
Market Landscape
The expansion follows the industry trend where biotech firms install seasoned leadership teams ahead of a transition to public markets. This move mirrors the staffing patterns seen in similar clinical-stage oncology companies preparing for higher visibility with public investors.
Operators in the biotech sector should track these leadership changes as a signal of a company's accelerating public-market roadmap. Evaluate how these specific hires affect the company's future deal-making capacity or its ability to secure new strategic partnerships.
The takeaway
Expanding your leadership bench with experienced personnel is a critical step for firms managing the complexity of a public transition. Monitor this executive team's progress in managing external partnerships to gauge the effectiveness of the firm's new strategic direction.
Further reading
For more on industry leadership trends, visit the People section.
Live Poll
Do you trust that new leadership at emerging biotech firms signals long-term stability for investors?
